Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

April 9, 2020, 5:52 p.m. EDT

BioCryst stock rallies on start of coronavirus drug study

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    BioCryst Pharmaceuticals Inc. (BCRX)

or Cancel Already have a watchlist? Log In

By Wallace Witkowski

BCRX

BioCryst Pharmaceuticals Inc. /zigman2/quotes/206499849/composite BCRX -0.12% shares rallied in the extended session Thursday after the drug maker said it was starting a clinical trial to test its COVID-19 treatment. BioCryst shares surged 35% after hours, following a 3.5% rise to close the regular session at $2.07. The company said it opened a randomized, double-blind, placebo-controlled clinical trial to test the drug galidesivir in treating patients with COVID-19. The study, which is being funded by the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, will be conducted in Brazil, the company said. Many drug companies have recently started development of either COVID-19 treatments or vaccines.

/zigman2/quotes/206499849/composite
US : U.S.: Nasdaq
$ 4.13
-0.0050 -0.12%
Volume: 2.83M
Aug. 11, 2020 12:31p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$728.54 million
Rev. per Employee
$206,530
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.